| Title |
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
|
|---|---|
| Published in |
OncoTargets and therapy, December 2022
|
| DOI | 10.2147/ott.s326632 |
| Pubmed ID | |
| Authors |
Prokop Vodicka, Pavel Klener, Marek Trneny |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Peru | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 64 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Unspecified | 4 | 6% |
| Student > Ph. D. Student | 4 | 6% |
| Other | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 34 | 53% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 19% |
| Biochemistry, Genetics and Molecular Biology | 7 | 11% |
| Unspecified | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 6% |
| Unknown | 35 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2022.
All research outputs
#14,551,100
of 25,392,582 outputs
Outputs from OncoTargets and therapy
#720
of 3,016 outputs
Outputs of similar age
#188,457
of 487,009 outputs
Outputs of similar age from OncoTargets and therapy
#6
of 22 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 487,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.